The plasma concentration of 6-keto-prostaglandin Fl, ), the stable hydration product of prostacyclin, was measured by radioimmunoassay in 111 healthy children aged between 1 day and 16 years and in 21 healthy adults aged between 21 and 72 years. The 6-ketoPGF1a levels in children up to age 16 years were higher than those in adults. During the first 4 days of life the plasma concentrations of 6-keto-PGF1, in term infants were higher (P <0 05) than the respective levels in preterm infants. There was no difference between the 6-keto-PGF1a levels measured simultaneously in umbilical arterial and peripheral venous plasma in 7 newborn infants. Maternal pre-eclampsia or epidural analgesia during labour, mode of delivery, birthweight, or sex of the infants were not related to the plasma 6-keto-PGF1, levels on the first day of life. High levels of vasodilatory and anti-aggregatory prostacyclin during the first days of life may play a role in the postnatal adaptation of the circulation and platelet function.
dilatory properties. PGI2 is unstable; most of it is rapidly converted non-enzymatically in physiological pH to 6-keto-prostaglandin Fla (6-keto-PGF1,), the concentration of which, in a biological sample, reflects the production of PGI2.1 PGI2 is the major product of prostaglandin biosynthesis in vascular tissues of fetal animals.2 3
The human umbilical cord and placental vessels also generate much PGI2 in vitro. 35 The vasodilatory PGI2 may contribute to the low peripheral resistance typical of the fetal circulation.46 7 There is evidence to suggest that PGI2 is important in adults,1 but little is known about the endogenous PGI2 in newborn infants or older children. Therefore we studied plasma PGI2 in children from birth to adolescence. Material and methods Subjects. One hundred and eleven healthy children were studied with the approval of the local committee of ethics. (-20qC ) until assayed for 6-keto-PGF1a with radioimmunoassay. Plasma was acidified to pH 3 with hydrochloride acid and extracted 4 times with ethyl acetate, The combined organic phases were evaporated to dryness under a nitrogen stream and two different parts, both in duplicate, of the residue dissolved in ethanol, were taken for the saturation analysis using specific antibodies raised in rabbits against 6-keto-PGF1a-bovine serum albumin conjugate and a tritiated tracer (New England Nuclear Corporation, Boston, Mass, USA). The specificity of the antibody was tested against 22 other prostaglandins or related compounds, and all crossreactions were less than 0 * 1 % at the 50 % displacement level, except for 6-keto-PGE1, which had a crossreaction of 1 * 8 %. The recovery of added 6-keto-PGF1a (50-200 pg/nil) into plasma was between 84 and 104% (n = 15), and the coefficients of intra-assay and interassay variations were between 6.8-8 5 and 9 3-14*2 %, respectively. The plasma 6-keto-PGF1a measurement as an index of PGI2 production was further validated by demonstrating a linear relationship (r = 0.958, P<0 001, n = 24) between infused PGI2 doses (1-8 ng/kg per min) and the rises in 6-keto-PGF1a levels in the plasma of 6 healthy adults. We could also show in vitro works that the release of radioimmunoassayable 6-keto-PGFIa by the umbilical cord vessels is inhibited with indomethacin in a concentration dependent manner, which gives further validation for 6-keto-PGF1a measurement.
Statistical analysis. The results were tested using the Mann Whitney rank sum test.
Results
Cord blood. The concentrations of 6-keto-PGF1a in umbilical arterial plasma (1002 ± 150 pg/ml; mean ± SE) were higher than those in umbilical venous plasma (538 ± 116 pg/ml; P<0-05) or in term infants on the first day of life (397 i 25 pg/ml; P<0.001). However, the 6-keto-PGF1a levels in umbilical venous blood did not differ from those in term infants on the first day of life (P>0.05).
Term infants.
The first day of life There was no difference (P>0.05) between the 6-keto-PGF1a levels in samples taken simultaneously from the umbilical artery (396 + 80 pg/ml) and the peripheral vein (410 + 65 pg/ml). Consequently, the neonatal concentrations of 6-keto-PGF,a measured in umbilical arterial or peripheral venous plasma were combined. The 6-keto-PGF1a levels on the first day of life were higher than those in older children and adults (Table) . Maternal pre-eclampsia The concentrations of 6-keto-PGFia stayed in the range of the first-day levels for the next 1-3 days, but rapidly fell at age 6-8 days (Table) . With advancing age of the children the 6-keto-PGFI.
concentrations declined towards the adult levels, but still in adolescence, the 6-keto-PGF1,a levels were higher than those in adults (Table) .
Preterm infants. The concentrations of 6-keto-PGF1a in preterm infants were lower (P<0.05) than those in term infants on the first 4 days of life, whereas no differences in these levels were found later (Table) . The age-dependent decrease in 6-keto-PGF1 a levels took place later in preterm than term infants (Table) .
Discussion
It is clear from our data that plasma PGI2, as measured by its metabolite in peripheral blood, is greatly increased during the first days of life. This may reflect the high PGI2 production typical for the fetal vasculature 2-5, as also seen from the high concentrations of 6-keto-PGF1a in the umbilical cord vessels in our study. Judged from the higher levels of 6-keto-PGF1a in the umbilical artery compared with umbilical vein, it seems likely that the fetal 6-keto-PGF1a contributes to the increased 6-keto-PGF1a concentrations in maternal plasma during pregnancy8 or labour.9 Perhaps the Plasma prostacyclin from birth to adolescence 461 fetus through this PGI2 surge helps to control the blood flow in its own placenta. Since PGI2 is produced particularly by the pulmonary vascular bed,'0 the high 6-keto-PGFIa levels on the first days of life might also be a consequence of the increased output of PGI2 by the newly ventilated lungs. This was suggested in a study that showed there was increased release of vasodilatory PGI2 from the fetal lung after the start of respiration." Our results further suggest that the fetal PGI2 synthesis is not fully matured before term, since the concentrations of 6-keto-PGF2a in preterm infants on the first days of life were significantly lower than those in term infants. The biological significance of the high PGI2 concentrations during the first days of life is not known. PGI2 could be the endogenous pulmonary vasodilator known to be present in newborn infants.'2 This is supported by the pulmonary vasodilatation after PGI2 infusions in near-term goats'3 and lambs. '4 In humans, the pulmonary vascular resistance decreases rapidly during the first few days of life.'1 This decrease matches well with the high PGI2 levels on the first 4 days we observed in our study. Thus our data could support the hypothesis of PGI2 as a pulmonary vasodilator. Increased production of anti-aggregatory PGI2 could also provide an explanation for the impaired platelet aggregation in newborn infants.'6 After the rapid decrease during the first week of life, the PGI2 levels declined slowly towards the adult values. Similar age-dependent decrease of PGI2 production has been found in rat aortas.'7 Perhaps this age-related PGI2 decline might provide one explanation for the changes in the haemodynamics observed in childhood-for example, the rise in systemic vascular resistance. 18 We conclude that the healthy term infant circulates more PGI2 than the healthy preterm infant, the older child, or adult. The involvement of PGI2 in neonatal disorders, such as persistent fetal circulation or respiratory distress syndrome, should be studied. 
